Pulmonary Hypertension SOLAR

PHASE2RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

November 8, 2023

Primary Completion Date

December 30, 2025

Study Completion Date

December 30, 2025

Conditions

Interstitial Lung DiseaseCOPDPulmonary Arterial Hypertension

Interventions

DRUG

Hyperpolarized 129Xe

Each xenon dose will be limited to a volume less than 25% of subject lung capacity (TLC),

Trial Locations (1)

RECRUITING

Duke University Medical Center, Durham

All Listed Sponsors

lead

Bastiaan Driehuys

OTHER